RMMS Secures Federal Circuit Ruling Affirming Trial Decision of Patent Invalidity Involving Generic Galantamine

September 25, 2009 | Small Molecules

09/25/2009 On September 25, 2009, the U.S. Court of Appeals for the Federal Circuit issued a ruling affirming the U.S. District Court for the District of Delaware’s finding that Janssen’s ‘318 patent is invalid for lack of enablement. This decision clears the way for the firm’s client to continue marketing its generic version of Janssen’s Razadyne® (galantamine), which the client launched after the successful trial decision in September 2008, and represents a significant victory for the generic industry in general. William Rakoczy argued the case before the Federal Circuit. Also involved in the underlying litigation and appeal was Christine Siwik.